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Abstract Antibody-mediated, humoral rejection has been
recognized as a common cause of transplant dysfunction and
is responsible for 30–50% of failed allografts. The production
of antibody is dependent on instructions from memory CD4+
T helper cells that interact with antigen-specific B cells. Re-
cently, a specialized T-cell subset has been identified—T
follicular helper (Tfh) cells—which support activated B cells
via interleukin (IL)-21 after binding to the IL-21 receptor
expressed by these B cells. Therefore, neutralizing the IL-21
pathway will selectively inhibit the allogeneic IL-21-driven
Tfh- and B-cell functions. However, little is known of the role
of Tfh cells in alloreactivity. In this review, we debate the role
of Tfh cells in B-cell-mediated allogeneic responses by
discussing their mechanisms of actions. In addition, we spec-
ulate about the use of agents that intervene in Tfh–B-cell
interaction and consequently prevent or treat antibody-
mediated rejection in patients after transplantation.
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Introduction
Annually, 100,000 transplantations are performed worldwide.
However, 50 % of the transplanted organs are lost within
10 years after transplantation [1]. This poor long-term out-
come is heavily influenced by B-cell-mediated humoral rejec-
tion, which has now been recognized as an important cause of
allograft loss [2, 3, 4••]. In particular, antibodies directed
against the transplanted organ (i.e., donor-specific antibodies
[DSA]) drive this irreversible and non-treatable process of
allograft rejection [4••, 5].
Histological Features of Alloreactivity
Transplant rejection is assessed by grading histopathologic
lesions followed by assigning diagnoses according to stan-
dardized but arbitrary criteria [6, 7•]. Cellular rejection is
mainly diagnosed by interstitial infiltration and is seen as a
process in which T cells are dominant. Antibody-mediated
rejection (ABMR), however, is recognized by inflammatory
cells in the microcirculation and the presence of anti-HLA
DSA reflecting a process in which B cells are the key players.
While the histological diagnosis of cellular rejection is clear,
the diagnosis of humoral rejection is subject to change.
Because of its association with preformed antibodies to
HLA in recipients, the vascular presence of complement
fragment C4d has been assumed to represent humoral
immune reaction against graft endothelial cells. The
importance of C4d was confirmed in multivariate anal-
ysis demonstrating that C4d is a strong predictor of
renal graft loss [2]. Yet, more recent studies also sup-
port the existence of ABMR with negative or minimal/
equivocal C4d deposition, which led to the recent revi-
sions of the histological criteria for ABMR [7•].
Nowadays it is clear that these two apparently differ-
ent processes of alloreactivity are not as different as
once thought. Overlapping histological features between
cellular and ABMR are often seen. The cellular compo-
sition of these mixed rejections displays T-cell and B-
cell infiltrates as well as the typical features of ABMR
like microvascular inflammation [3, 7•, 8]. The impor-
tance of B cells in cellular rejection was also demon-
strated in studies using gene-profiling approaches. The
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landmark paper by Sarwal et al. reported a B-cell sig-
nature at the molecular level in one third of the biopsies
during acute cellular rejection [9]. These findings also
implicate that T-cell–B-cell interactions not only occur
in the secondary lymphoid organs but also may interact
locally in the transplanted organ, which is further sup-
ported by the organization of these T- and B-cell infil-
trates in lymphoid organ-like structures (Fig. 1; [10,
11]).
Tertiary Lymphoid Organs in Human Allografts
B cells together with Tcells and dendritic cells form organized
follicular structures surrounded by neo-lymphatic vessels.
These nodular infiltrates contain the entire repertoire of T
and B cells which may give rise to the specific cellular and
humoral alloantigenic immune responses by proliferating
CD4 and CD8 T cells and plasmacytoid cells. The clinical
relevance of these structures has been shown in autoimmunity
where lymphoid follicles are associated with more aggressive
disease and a worse clinical outcome [12]. The contribution of
these tertiary lymphoid organs to alloimmunity is still un-
known and deserves attention.We speculate that future studies
will show that these tertiary lymphoid structures in the
transplanted organ provide the perfect conditions for local T-
cell–B-cell interactions resulting in B-cell proliferation, dif-
ferentiation, and production of DSA during allogeneic im-
mune responses.
Novel Insights in T-cell–B-cell Interactions
The production of antibody is dependent on instructions from
memory CD4+ T helper cells that recognize the same antigen
in germinal centers [13••, 14]. It is now known that this
cognate help is mediated by a specialized CD4+ T-cell subset,
termed T follicular helper cells (Tfh) (Fig. 2) [13••, 14, 15].
These non-Th1/Th2/Th17 effector CD4+ T cells express high
levels of CXCR5, which, in conjunction with the loss of
CCR7, enables them to localize to B-cell follicles and germi-
nal centers of secondary lymphoid during T-cell-dependent
immune responses [13••]. The presence of tertiary structures
in the allograft suggests that alloantigen-activated Tfh cells
can interact with B cells in these tertiary lymphoid organs. The
capacity of Tfh cells to provide help to B cells depends upon
the acquisition of molecules that are known to play functional
roles in T-cell–B-cell interactions, like the co-stimulatory
molecules CD40 ligand, inducible costimulator (ICOS), pro-
grammed death 1 (PD-1), and the cytokine interleukin (IL)-
21. Tfh cells have the highest levels of these molecules
and the expression levels correlate with the ability to
facilitate antibody production. The transcriptional repres-
sor B-cell lymphoma (BCL)-6 is the master regulator of
Tfh differentiation [13••, 15, 16••]. Tfh cells contain the
capacity to support immunoglobulin production when
co-cultured with B cells. These T cells respond to
CXCL13, which is also known as B lymphocyte
chemoattractant, with higher levels IL-21, interferon
(IFN)-γ and IL-4 upon restimulation [17].This chemo-
kine is secreted by dendritic cells, and is expressed
highly in the liver, spleen, lymph nodes, and gut of
humans as well as in the allograft during rejection
[18•, 19]. The importance of CXCL13 was shown in
blocking studies where neutralization of CXCL13 completely
disrupts the follicular structure in lymphoid organs. Addition-
al signals from the microenvironment such as IL-6 support the
generation of B-helper capacity.
Fig. 1 Cellular infiltrates in acute cellular rejection after kidney trans-
plantation. A: Hematoxylin Eosin (HE) staining showing cellular infil-
trates. B: aspecific background staining with C4d. C–E: co-localization of
T helper cells, CD3- and CD4-positive cells in C and D, and B cells,
CD20-positive cells in E. Magnification A–B: 20×, C–E: 10×, insert: 20×
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Peripheral (p)Tfh Cells
Recent developments in the identification of these cells in the
circulation created the possibility to study the immunological
functions and molecular composition of antigen-activated Tfh
cells at large. In contrast to Tfh cells present in the secondary
lymphoid tissues, their peripheral counterparts, characterized
as CXCR5+CD4+ T cells, do not express Bcl-6 and express
lower levels of ICOS and PD-1. Both Tfh and peripheral
(p)Tfh cells secrete IL-21 upon stimulation, which has an
essential role in B-cell activation, expansion, and plasma-cell
generation [13••, 16••]. The identification of the pTfh-cell
population in the circulation boosted the field and many
papers on the role of these cells have recently been published
in auto-immune diseases like systemic lupus erythematosus,
rheumatoid arthritis, and chronic viral infections [20–25].
Importantly, these papers show that higher frequencies of
pTfh cells are positively correlated with the blood levels of
disease-specific auto-antibodies and with disease activity.
Moreover, dysregulation of the IL-21 pathway has been
shown to be associated with these chronic inflammatory dis-
eases and, in animal models, inhibition of the IL-21 pathway
reduced disease activity.
IL-21
IL-21 is an interesting member of the IL-2 family of cytokines
that plays important roles in multiple T-helper subsets. Both
Tfh cells and Th17 cells are known to produce this pleiotropic
cytokine which functions in both an autocrine and paracrine
manner [26]. IL-21 signals through the heterodimeric IL-21
receptor plus the common cytokine receptor γ-chain by phos-
phorylation of the transcription factor STAT3. The best-
described effects of IL-21 are the promotion of CD8+ T-cell
expansion as well as immunoglobulin production and differ-
entiation of B cells into antibody-producing plasma cells by
the induction of the transcriptional regulators controlling the
major fates of B-cell differentiation: Bcl-6 and BLIMP [27,
28••]. Recently, it was reported that this cytokine also acts as
an inducer of the costimulatory ligand CD86 on B cells [29].
In addition, IL-21 has an inhibitory effect on regulatory Tcells
and the other T cell helper subsets [30]. We demonstrated that
IL-21 is an essential cytokine in T-cell dominated
alloreactivity by measuring high expression levels of IL-21
and IL-21R during acute cardiac rejection, while blockade of
the IL-21 pathway specifically inhibited the expansion of
donor antigen-activated T cells in vitro [31]. The role of IL-
Fig. 2 Differentiation of Tfh cells. After antigen activation, naïve CD4+
T cells differentiate into activated T cells that express high levels of
CXCR5, inducible costimulator (ICOS), and programmed death 1 (PD-
1). However, only cells that differentiate into follicular T helper (Tfh)
cells keep the highest expression of these markers. Tfh cells produce high
levels of IL-21, which functions as an autocrine factor for the expansion
of Tfh cells. BCL-6 has been identified as the master regulator for Tfh
cells
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21 in ABMR comes from the recently published study by
Knechtle et al., who clearly demonstrated, in a nonhuman
primate kidney transplant model, that IL-21 production was
found inside the germinal centers of lymph nodes in animals
with signs of ABMR [32••].
Rationale for Measuring Follicular T Cells in Organ
Transplantation
The immunosuppressive medication currently given to
transplant patients fails to show potent, selective immu-
nosuppression as many transplant recipients develop a
humoral donor-specific antibody response which may
result in irretrievable graft loss. It is useful to perform
immune monitoring to gain insight into the mechanisms
behind this lack of efficacy and to better understand the
role of Tfh and their peripheral counterparts in T-cell
dependent B-cell alloreactivity. This will answer ques-
tions about the functions of this helper T-cell subset in
immune responses of patients with organ failure and
after transplantation. By immune monitoring, the follow-
ing questions will be unravelled: are Tfh cells funda-
mental in antibody-mediated alloreactivity? If so, do Tfh
cells home in the allograft? What is their behavior in
the periphery? Do immunosuppressants influence the
number and function of these Tfh cells? In the next
section we will discuss these questions together with
the latest developments in immunosuppressive drugs
targeting Tfh-controlled immune responses.
Presence of Tfh Cells in Secondary and Tertiary Lymphoid
Tissues After Transplantation
Up to now, two studies have reported on Tfh cells in lymph
nodes in the transplantation setting. First, early DSA produc-
tion was observed in a nonhuman primate kidney transplant
model in which the immunosuppressive regimen used
consisted of anti-CD3 immunotoxin, tacrolimus, and alefacept
(an anti-CD2 monoclonal antibody). Analysis of their second-
ary lymphoid tissues showed clear evidence of proliferating B
cells plus Bcl-6 expressing CD4 T cells and IL-21 expression
[32••]. Additional immunosuppression, in the form of
blocking the co-stimulation pathways CD28-CD80/86 and
CD40-CD40 ligand, attenuated the induction of de novo
DSA. Moreover, decreased numbers of Bcl-6+ CD4 T cells
and less IL-21 protein expression were found in these tissues.
The second paper describing the function of Tfh cells
comes from van Lier and colleagues. These authors focus on
the CD4 T cell subset composition and function of Tfh cells
present in lymph nodes from kidney transplant candidates
[33•]. For the Tfh cells, the following was reported: the
percentage of Tfh cells, defined as CXCR5+ CD4+T cells,
was about 25 % in resting lymph nodes and significantly
higher than in the circulation (5–12 %). These lymph node-
derived Tfh cells exhibit more advanced B-cell help compared
with their peripheral counterparts. Overall, this study shows
that Tfh cells remain functional in patients with end-stage
renal disease. However, whether these Tfh cells also trigger
B-cell-mediated immune responses in immunosuppressed pa-
tients after transplantation was not studied and is still a ques-
tion to be answered. This type of research is of course difficult
as access to human post-transplantation lymphoid tissue is
limited, if not impossible. In contrast, the availability of clin-
ical biopsies creates the possibility to study the actions of Tfh
cells in the allograft. For example, after heart transplantation,
biopsies are routinely taken for the diagnosis of rejection. In
these samples, Quilty lesions are often found that show the
characteristic features of lymphoid structures and comprise T
cells and B cells. These lesions are seen as local sites of
antigen processing and immune stimulation [34]. Therefore,
this clinical model provides the unique opportunity to charac-
terize these T-cell infiltrates in detail and study their dynamic
influx and interactions with B cells, which will provide an-
swers to the key questions around kinetics and functions of
Tfh cells in allograft rejection and whether Tfh cells home in
the allograft.
Our pilot study analyzing the role of Tfh cells in kidney
transplantation suggests that these cells might be present in the
cellular infiltrates in the transplanted kidney. In biopsies taken
to confirm acute rejection, cellular rejection Bcl-6 positive
cells are found on the border of T-cell–B-cell infiltrates after
kidney transplantation. Whether these Bcl-6-positive cells
are indeed Tfh cells needs to be confirmed by
counterstaining with CD3 to confirm their T-cell origin.
We speculate that, in transplant patients, these special-
ized T cells migrate to the allograft where they provide
help to the infiltrated B cells, resulting in their differ-
entiation into IgG-secreting plasma cells. Therefore,
characterization of graft-infiltrated Tfh cells by their
function and molecular signature will expand our
knowledge on how ABMR is controlled by Tfh cells.
Peripheral (p)Tfh Cells and Transplantation
In addition to the analysis of the graft-infiltrated Tfh cells,
knowledge about the specific features of patient-derived pTfh
cells will also contribute to a better understanding of the
involvement of Tfh cells in ABMR. For that purpose, we
studied pTfh cells in kidney transplant patients before and in
the first months after transplantation. Our first results analyz-
ing pTfh cells defined as IL-21+CXCR5+CD4+ T cells,
showed that numbers of Tfh cells before and after transplan-
tation are associated with the immunization status of the
patient and presence of pre-existing DSA resulting from pre-
vious transplantations [35]. Furthermore, the in vitro co-
culture studies revealed that the pTfh cells in the presence of
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antigen provided help to B cells which resulted in the produc-
tion of IgM and IgG. In the presence of IL-21 receptor
antagonists, this response was significantly inhibited as pTfh,
B-cell numbers and immunoglobulin production were affect-
ed by IL-21 blockade (Fig. 3). These results show that, also in
kidney transplant patients, pTfh cells can provide help to B
cells. The easy access to the peripheral blood compart-
ment provides the unique opportunity to monitor pTfh-
regulated B-cell alloreactivity over time in transplant
patients, which will reveal insights in their behavior
during immunological activity and quiescence. Our first
data are promising and hint towards neutralization strat-
egies of the IL-21 pathway to effectively inhibit Tfh-
cell-mediated B-cell activation. More data and studies
are needed to draw conclusions on the role of Tfh cells
in the transplantation clinic and how to best target this
T-cell subset by immunosuppressive medication.
New Therapeutic Approaches
No specific treatment for ABMR has been registered to
date and available therapeutic options result from off-
label repurposing of costly drugs. After the diagnosis
of ABMR, patients are aggressively treated with agents
like plasmapheresis, immune modulation via intrave-
nous immunoglobulins (IVIg), alemtuzumab (anti-
CD52), rituximab (anti-CD20), BAFF-R inhibitors (B-
cell-activating factor receptor belonging to the TNF
receptor superfamily), bortezomib (proteasome inhibi-
tor) and eculizumab (targets complement cascade);
drugs that not always properly inhibit the rejection
process. Therapies specifically designed to prevent
and treat ABMR in transplant recipients are lacking,
which in light of the severity and frequency of ABMR
is unacceptable. Our pilot studies showed that anti-IL-
21R antibodies specifically target the T-cell–B-cell in-
teraction, resulting in significant reduction of Tfh num-
bers and IgM/IgG production by plasma cells. Also,
blockade of the IL-21 pathway with chimeric IL-21R
fusion proteins and anti-IL21R antibodies in animal
models of rheumatoid arthritis and lupus showed sig-
nificantly less disease activity as well as reduced B-cell
reactivity [36–38]. The promising data in autoimmune
models directed the development of fully humanized
IL-21R antibodies by pharmaceutical companies with
first published data on safety, pharmacokinetics, and
pharmacodynamics in healthy volunteers [39••]. Wheth-
er these agents also influence Tfh-dependent B-cell
activation and differentiation in organ transplantation
is unknown and studies using experimental transplant
models are therefore heavily warranted. The outcome
of these studies will be translated to the clinical situa-
tion and opens avenues to prevent and better treat
ABMR in transplant recipients.
Conclusions
We plea for a key role of IL-21 producing Tfh cells in
ABMR after organ transplantation. Investigating mecha-
nisms of T- and B-cell cross‐talking in transplant pa-
tients will deepen our understanding of the immunology
behind ABMR and, in particular, about the IL-21+ Tfh–
B-cell interaction. We speculate that intervention of the
IL-21 pathway has huge therapeutic potential: it will
selectively inhibit allogeneic IL-21 driven T-cell and
B-cell functions, which will be a novel and effective
way to safely prevent and treat ABMR in organ trans-
plant patients.
Compliance with Ethics Guidelines
Conflict of Interest Carla C. Baan, Ph.D, Gretchen N. de Graav, MD,
and Karin Boer declare that they have no conflicts of interest.
Fig. 3 An antagonist of the IL-21 receptor (IL-21-R-antagonist) success-
fully inhibited peripheral follicular T helper (pTfh) cell functions in vitro.
Memory B cells were co-cultured for 7 days with pTfh-cells in the
presence of super antigen B. In addition, we added an IL-21-R-antagonist
or an isotype IgG control to the co-cultures. After 7 days, we measured
the percentage of memory B cells (Mem B) that survived; the percentage
of memory B cells that differentiated into plasmablasts (PB); the IgM
production (ng/mL); and the IgG production (ng/mL). Here a represen-
tative sample is depicted of the outcomes in the presence of an IL-21-R-
antagonist compared with IgG control. The IgG isotype is set to 100 %.
The concentration of IL-21-R-antagonist added was 5 μg/mL, corre-
sponding to the IC50 [16••, 35]
170 Curr Transpl Rep (2014) 1:166–172
Human and Animal Rights and Informed Consent This article does
not contain any studies with human or animal subjects performed by any
of the authors.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Organ procurement and transplantation network and scientific reg-
istry network and scientific registry of transplant recipients 2010
data report. Am J Transplant. 2012;12:1-156.
2. Lederer SR, Kluth-Pepper B, Schneeberger H, Lederer SR, Kluth-
Pepper B, Schneeberger H. Impact of humoral alloreactivity early
after transplantation on the long-term survival of renal allografts.
Kidney Int. 2001;59:334–41.
3. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF,
Campbell PM, et al. Antibody-mediated rejection criteria – an
addition to the Banff ’97 classification of renal allograft rejection.
Am J Transplant. 2003;3:708–14.
4.•• Loupy A, Lefaucheur C, Vernerey D, Prugger C, van Duong van
Huyen JP, Mooney N, et al. Complement-binding anti-HLA anti-
bodies and kidney-allograft survival. N Engl J Med. 2013;369(13):
1215–26. The study reporting that graft survival after kidney trans-
plantation is largely influenced by complement-fixing DSA and not
by the non-complement-fixing DSA.
5. Sellares J, Cecka JM, Kasiske BL, Reeve G, Einecke B, Sis
L, et al. Evidence of antibody –mediated injury as a major
determinant of late kidney allograft failure. Am J Transplant.
2012;12:388–99.
6. Stewart S, Winters GL, Fishbein MC, Tazelaar HD,
Kobashigawa J, Abrams J, et al. Revision of the 1990
working formulation for the standardization of nomenclature
in the diagnosis of heart rejection. J Heart Lung Transplant.
2005;24:1710–20.
7.• Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin
RB, et al. Banff 2013 meeting report: inclusion of C4d-
negative antibody-mediated rejection and antibody-
associated arterial lesions. Am J Transplant. 2014;14:272–
83. The importance of Cd4-negative rejection in antibody-
mediated rejection is recognized and accepted by the
transplantation community.
8. Loupy A, Cazes A, Guillemain R, Amrein C, Hedjoudje A,
Tible M, et al. Very late heart transplant rejection is associ-
ated with microvascular injury, complement deposition and
progression to cardiac allograft vasculopathy. Am J Transplant.
2011;11:1478–87.
9. SarwalM, ChuaMS, KambhamN,Hsieh SC, Satterwhite T,Masek
M, et al. Molecular heterogeneity in acute renal allograft rejection
identified by DNA microarray profiling. N Engl J Med. 2003;349:
125–38.
10. Jonigk D, LehmannU, Stuht S,WilhelmiM,Haverich A, Kreipe H,
et al. Recipient-derived neoangiogenesis of arterioles and lym-
phatics in quilty lesions of cardiac allografts. Transplantation.
2007;84(10):1335–42.
11. Motallebzadeh R, Bolton EM, Pettigrew GJ. Lymphoid tissue for-
mation in allografts: innocent until proven guilty. Transplantation.
2008;85(3):309–11.
12. Pender MP, Greer JM. Immunology of multiple sclerosis. Curr
Allergy Asthma Rep. 2007;7(4):285–92.
13.•• Tangye SG, Ma CS, Brink R, Deenick EK. The good, the bad and
the ugly - TFH cells in human health and disease. Nat Rev
Immunol. 2013;13(6):412–26. Great review summarizing the cur-
rent knowledge on Tfh and peripheral (p)Tfh cells.
14. Fazilleau N, Mark L, MacHeyzer-Williams LJ, McHeyzer-Willems
NG. Follicular helper T cells: lineage and location. Immunity.
2009;30:324–35.
15. Yu D, Rao S, Tsai LM, Lee SK, He Y, Sutcliffe EL, et al. The
transcriptional repressor Bcl-6 directs T follicular helper cell lineage
commitment. Immunity. 2009;31(3):457–68.
16.•• Morita R, Schmitt N, Bentebibel SE, Ranganathan R, Bourdery L,
Zurawski G, et al. Human blood CXCR5(+)CD4(+) T cells are
counterparts of T follicular cells and contain specific subsets that
differentially support antibody secretion. Immunity. 2011;34(1):
108–21. One of the first papers showing that human peripheral
Tfh cells, defined as CXCR5+ Cd4+ T cells, provide the proper
costimulatory and cytokine signals to activate B cells.
17. Steinmetz OM, Panzer U, Kneissler U, Harendza S, Lipp M,
Helmchen U, et al. BCA-1/CXCL13 expression is associated with
CXCR5-positive B-cell cluster formation in acute renal transplant
rejection. Kidney Int. 2005;67(4):1616–21.
18.• Siepert A, Brösel S, Vogt K, Ahrlich S, Schmitt-Knosalla I,
Loddenkemper C, et al. Mechanisms and rescue strategies of cal-
cineurin inhibitor mediated tolerance abrogation induced by anti-
CD4 mAb treatment. Am J Transplant. 2013;13(9):2308–21. This
paper nicely describes the role of CXCL13 in allograft rejection.
19. Finch DK, Ettinger R, Karnell JL, Herbst R, Sleeman MA. Effects
of CXCL13 inhibition on lymphoid follicles in models of autoim-
mune disease. Eur J Clin Invest. 2013;43(5):501–9.
20. Le Coz C, Joublin A, Pasquali JL, Korganow AS, Dumortier H,
Monneaux F. Circulating TFH subset distribution is strongly affect-
ed in lupus patients with an active disease. PLoS One. 2013;8:
e75319.
21. Ma J, Zhu C, Ma B, Baidoo SE, Mao C, et al. Increased frequency
of circulating follicular helper T cells in patients with rheumatoid
arthritis. Clin Dev Immunol. 2012;2012:827480.
22. Zhu C, Ma J, Liu Y, Tong J, Tian J, Chen J, et al. Increased
frequency of follicular helper T cells in patients with autoimmune
thyroid disease. J Clin Endocrinol Metab. 2012;97:943–50.
23. Cubas RA, Mudd JC, Savoye AL, et al. Inadequate T follicular cell
help impairs B cell immunity during HIV infection. Nat Med.
2013;19:494–9.
24. Lindqvist M, van Lunzen J, Soghoian DZ, Kuhl BD, Ranasinghe S,
Kranias G, et al. Expansion of HIV-specific T follicular helper cells
in chronic HIV infection. J Clin Invest. 2012;122:3271–80.
25. Li Y, Ma S, Tang L, Wang W, Huang X, Lai Q, et al.
Circulating chemokine (C-X-C Motif) receptor 5(+) CD4(+)
T cells benefit hepatitis B antigen seroconversion through
IL-21 in patients with chronic hepatitis B virus infection.
Hepatology. 2013;58:1277–86.
26. Spolski R, LeonardWJ. Interleukin-21: basic biology and implications
for cancer and autoimmunity. Annu Rev Immunol. 2008;26:57–79.
27. Avery DT, Deenick EK, Ma CS, Suryani S, Simpson N, Chew GY,
et al. B cell–intrinsic signaling through IL-21 receptor and STAT3 is
required for establishing long-lived antibody responses in humans.
J Exp Med. 2010;207(1):155–71.
28.•• RecherM, Berglund LJ, Avery DT, CowanMJ, Gennery AR, Smart
J, et al. IL-21 is the primary common γ chain-binding cytokine
required for human B-cell differentiation in vivo. Blood.
2011;118(26):6824–35. Study showing the crucial role of IL-21 in
B-cell activation and B-cell differentiation.
Curr Transpl Rep (2014) 1:166–172 171
29. Attridge K, Kenefeck R, Wardzinski L, Qureshi OS, Wang CJ,
Manzotti C, et al. Il-21 promotes CD4 T cell responses by phos-
phatidylinositol 3-kinase-dependent upregulation of CD86 on B
cells. J Immunol. 2014;192:2195–01.
30. Attridge K, Wang CJ, Wardzinski L, Kenefeck R, Chamberlain JL,
Manzotti C, et al. IL-21 inhibits T cell IL-2 production and impairs
Treg homeostasis. Blood. 2012;119:4656–64.
31. Baan CC, Balk AHMM, Dijke IE, Korevaar SS, Peeters AM, de
Kuiper RP, et al. IL-21: an IL-2 dependent player in rejection
processes. Transplantation. 2007;83:1485–92.
32.•• Kim EJ, Kwun J, Gibby AC, Hong JJ, Farris 3rd AB, Iwakoshi NN,
et al. Costimulation blockade alters germinal center responses and
prevents antibody-mediated rejection. Am J Transplant.
2014;14(1):59–69. First study reporting on a role for Tfh cells in
allograft rejection in a non-human primate model.
33.• Havenith SH, Remmerswaal EB, Idu MM, van Donselaar-van der
Pant KA, van der Bom N, Bemelman FJ, et al. CXCR5+CD4+
follicular helper T cells accumulate in resting human lymph nodes
and have superior B cell helper activity. Int Immunol. 2014;26(3):
183–92. This study nicely shows that lymph node-derived Tfh cells
remain functional in patients with end-stage renal disease.
34. Chu KE, Ho EK, de la Torre L, Vasilescu ER, Marboe CC. The
relationship of nodular endocardial infiltrates (Quilty lesions) to
survival, patient age, anti-HLA antibodies, and coronary artery
disease following heart transplantation. Cardiovasc Pathol.
2005;14:219–24.
35. Graav De G, Dieterich M, Hesselink DA, Boer K, Clahsen M,
Kraaijeveld R, et al. Disrupting follicular T-helper cell driven B-
cell stimulation by IL-21-Receptor blockade is a novel therapeutic
option in kidney-transplant patients. World Transplant Congress,
2014; Abstract #310.
36. Young DA, Hegen M, Ma HL, Whitters MJ, Albert LM, Lowe L,
et al. Blockade of the interleukin-21/interleukin-21 receptor path-
way ameliorates disease in animal models of rheumatoid arthritis.
Arthritis Rheum. 2007;56:1152–63.
37. Rankin AL, Guay H, Herber D, Bertino SA, Duzanski TA, Carrier
Y, et al. IL-21 receptor is required for the systemic accumulation of
activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice.
Immunology. 2012;188(4):1656–67.
38. Vugmeyster Y, Guay H, Szklut P, Qian MD, Jin M,Widom A, et al.
In vitro potency, pharmacokinetic profiles, and pharmacological
activity of optimized anti-IL-21R antibodies in a mouse model of
lupus. MAbs. 2010;2(3):335–46.
39.•• Hua F, Comer GM, Stockert L, Jin B, Nowak J, Pleasic-
Williams S, et al. Anti-IL21 receptor monoclonal antibody
(ATR-107): Safety, pharmacokinetics, and pharmacodynamics
evaluation in healthy volunteers: A phase I, first in human
study. J Clin Pharmacology. 2013; First study on a human
monoclonal anti-IL21 receptor antibody. Il21 receptor ex-
pression on B cells was nicely blocked. However, a substan-
tial number of the healthy subjects developed anti-drug
antibodies.
172 Curr Transpl Rep (2014) 1:166–172
